FindTrial
Sign In

Racotumomab

BIOLOGICAL5 trials

Sponsors

Laboratorio Elea Phoenix S.A., Recombio SL, Center of Molecular Immunology (CIM)

Conditions

Advanced Non-small Cell Lung CancerAdvanced non small cell lung cancerEwing's SarcomaGliomaLung Cancer, Non-small CellNSCLCNeuroblastomaRetinoblastoma

Early Phase 1

Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory
Active, not recruitingRPCEC00000279
Center of Molecular Immunology (CIM)Advanced non small cell lung cancer
Start: 2018-07-09Updated: 2026-03-30

Phase 1

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
CompletedNCT01598454
Laboratorio Elea Phoenix S.A.Ewing's Sarcoma, Glioma, Neuroblastoma +2
Start: 2011-02-28End: 2015-06-30Updated: 2015-07-29

Phase 2

Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
CompletedNCT01240447
Laboratorio Elea Phoenix S.A.Advanced Non-small Cell Lung Cancer
Start: 2009-09-30End: 2014-06-30Updated: 2014-07-10
Racotumomab in Patients With High-risk Neuroblastoma
CompletedNCT02998983
Laboratorio Elea Phoenix S.A.Neuroblastoma
Start: 2016-11-30End: 2022-11-30Target: 39Updated: 2023-09-11

Phase 3

Immunotherapy With Racotumomab in Advanced Lung Cancer
NCT01460472
Recombio SLLung Cancer, Non-small Cell, NSCLC
Start: 2010-09-30End: 2016-09-30Target: 1082Updated: 2016-07-29

Related Papers

Ganglioside therapy in cancer molecular insights and therapeutic opportunities.
2025-11-24